Glenn David - Zoetis Chief Financial Officer, Executive Vice President

ZTS -- USA Stock  

Quarterly Earning Report: November 7, 2019  

Mr. Glenn David serves as Chief Financial Officer and Executive Vice President of the Company. Mr. David has played a key role in leading the financial operations for Zoetis since its initial public offering in 2013. He served as our Senior Vice President of Finance Operations from 2013 to 2016 and as acting Chief Financial Officer from April 2014 through August 2014
Age: 46  President Since 2016      
973 822-7000
David joined Pfizer in 1999 and held various financial roles, including Vice President of Global Finance for Pfizer Animal Health, our predecessor company, and Vice President of Finance for the U.S. Primary Care franchise.

Glenn David Latest Insider Activity

Management Efficiency

The company has Return on Asset of 12.56 % which means that on every $100 spent on asset it made $12.56 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 62.6 % implying that it generated $62.6 on every 100 dollars invested.
The company has 6.65 B in debt with debt to equity (D/E) ratio of 275.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. Zoetis has Current Ratio of 4.09 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Svend AndersenPerrigo Company Plc
Jeffrey NeedhamPerrigo Company Plc
James MichaudPerrigo Company Plc
Douglas BoothePerrigo Company Plc
Samiran DasDr Reddys Laboratories Ltd
J RamachandranDr Reddys Laboratories Ltd
Alok SonigDr Reddys Laboratories Ltd
Jatin ShahPerrigo Company Plc
Paul WeningerPerrigo Company Plc
George YancopoulosRegeneron Pharmaceuticals
K RaoDr Reddys Laboratories Ltd
Paul SilvaVertex Pharmaceuticals Incorpor
Joseph LaRosaRegeneron Pharmaceuticals
Amit SachdevVertex Pharmaceuticals Incorpor
Christopher FenimoreRegeneron Pharmaceuticals
Saumen ChakrabortyDr Reddys Laboratories Ltd
Douglas McCorkleRegeneron Pharmaceuticals
Amit BiswasDr Reddys Laboratories Ltd
Scott JamisonPerrigo Company Plc
James DillardPerrigo Company Plc
Daniel PlewRegeneron Pharmaceuticals

Entity Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 10000 people.Zoetis (ZTS) is traded on BATS Exchange in USA and employs 10,000 people.

Zoetis Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy
William Steere, Independent Director
Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications
Linda Rhodes, Independent Director
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, Executive Vice President, President - Research and Development
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, Chief Executive Officer, Director

Stock Performance Indicators

Current Sentiment - ZTS

Zoetis Investor Sentiment

Greater number of Macroaxis users are at this time bullish on Zoetis. What is your take regarding investing in Zoetis? Are you bullish or bearish?
98% Bullish
2% Bearish

Also Currentnly Active

Purchased few shares of
a day ago
Traded for 177.06
Purchased over 300 shares of
a day ago
Traded for 8.78
Purchased over 70 shares of
a day ago
Traded for 35.57
See also Your Current Watchlist. Please also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. drill down to check world indexes.